Browse the evidence

Reoperation odds among ACDF/GLP-1RA patients were significantly reduced at 12 months (4% vs. 6%; OR=0.689) and 24 months postoperatively (5% vs. 7%; OR=0.692).

GLP-1RAs may help reduce the need for reoperation in ACDF patients.

GLP-1RA use was associated with significantly reduced odds of pseudarthrosis by more than 20% and reoperation by more than 30% at 24 months following ACDF.

GLP-1RAs may significantly improve postoperative outcomes in ACDF patients.

GLP-1 receptor agonists (GLP-1RAs) reduce the risk of major adverse cardiovascular events and non-fatal stroke in patients with type 2 diabetes mellitus.

Practitioners should consider GLP-1RAs as a therapeutic option for reducing cardiovascular risks in patients with type 2 diabetes.

GLP-1RAs provide direct neurovascular protection by stabilizing the blood-brain barrier and modulating neuroinflammation.

GLP-1RAs may be beneficial in protecting brain health and reducing stroke risk.

Meta-regression showed no significant effect modification by age, body mass index, HbA1c, follow-up duration, or sodium-glucose co-transporter 2 inhibitors use.

The effectiveness of semaglutide is consistent regardless of these common patient characteristics.

Several classes of medications have been explored to target different pathways and receptors to preserve lean body mass during weight loss.

Practitioners may consider pharmacological options to help preserve muscle mass during weight loss.

Excess visceral abdominal fat (EVAF) can occur in people living with HIV-1 even with normal or mildly elevated body mass index (BMI).

Healthcare providers should assess visceral fat in PLWH regardless of BMI.

There were no significant differences in the amount of weight lost between semaglutide 0.5 mg and liraglutide 3 mg after 3 months.

Clinicians can expect similar weight loss outcomes from either treatment option.

Over half (60%) of participants with a BMI indicating obesity had no clinical diagnosis of obesity in their EHRs.

Clinicians should be aware that a significant number of patients with obesity may not be diagnosed, potentially leading to untreated health issues.

Men, and particularly NH-Asian men, may be at heightened risk of underdiagnosis of obesity.

Awareness of potential underdiagnosis in specific male populations can improve obesity management strategies.

GLP-1RAs are being studied in clinical settings not previously examined in original trials.

Practitioners should stay informed about the evolving applications of GLP-1RAs in clinical practice.

Patients who have undergone significant weight loss are at increased risk of thromboembolic events, particularly after body contouring procedures.

Practitioners should monitor thromboembolic risk in post-weight-loss patients undergoing surgery.

There have been some adjustments in weight reduction medications available on the German market in the last two years.

Stay updated on the latest weight reduction medications available in Germany.

The article provides an outlook on new weight reduction medications that are about to be approved or are currently in Phase 3 of approval studies.

Be aware of new medications that may soon be available for weight reduction.

Factors such as autonomic dysfunction, left atrial stretch, inflammation, and hormonal imbalances contribute to AF in obese individuals.

Understanding these factors can help in developing targeted interventions for AF in obesity.

The management of type 2 diabetes (T2D) has evolved significantly with the emergence of diverse medication classes.

Healthcare professionals should be aware of the evolving medication landscape for T2D.

There are challenges to the use of GLP-1 RAs, including drug expense and availability.

Healthcare providers should be aware of the barriers to access when prescribing GLP-1 RAs.

The article provides an overview of available GLP-1 RAs, their mechanisms of action, indications, adverse reactions, and risks.

Providers can refer to this overview for practical information on GLP-1 RAs.

Naltrexone/bupropion may benefit sexual desire through mood improvement.

Practitioners might consider Naltrexone/bupropion for patients seeking improvements in sexual desire linked to mood.

DPP-4 inhibitors offer stroke prevention and cognitive advantages, particularly in patients with renal impairment.

DPP-4 inhibitors may be considered for patients at risk of stroke and cognitive decline.

The findings suggest potential neurobehavioral benefits associated with incretin-based therapies (IBTs) in a high-risk population.

These findings may guide clinicians in selecting appropriate treatments for patients at risk of AUD post-surgery.

Recent progress in glucose-responsive systems enables real-time, glucose-triggered therapeutic activation.

This technology could lead to more effective and responsive diabetes treatments.

Hemoglobin A1c decreased across all groups but remained consistently higher in NHB and H compared with NHW at 24 months.

Monitoring of Hemoglobin A1c levels should be tailored based on race and ethnicity post-surgery.

NHB participants reported higher perceived discrimination, sleep disturbance, and perceived stress than H and NHW participants at all time points.

Addressing psychosocial factors is crucial for improving surgical outcomes in NHB patients.